Stockscreener 앱 받기
1.37
0.74%
0.01
시장 영업 전:
1.38
0.010
+0.73%
전일 마감가:
$1.36
열려 있는:
$1.38
하루 거래량:
8,349
Relative Volume:
0.11
시가총액:
$3.99M
수익:
$129.20K
순이익/손실:
$-7.44M
주가수익비율:
-0.1224
EPS:
-11.19
순현금흐름:
$-8.62M
1주 성능:
+8.73%
1개월 성능:
+0.74%
6개월 성능:
-77.20%
1년 성능:
-90.27%
1일 변동 폭
$1.33
$1.39
1주일 범위
$1.215
$1.45
52주 변동 폭
$1.10
$16.00
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile
명칭
Sonnet Biotherapeutics Holdings Inc
전화
609-375-2227
주소
100 OVERLOOK CENTER, PRINCETON, NJ
SONN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SONN
Sonnet Biotherapeutics Holdings Inc
|
1.37 | 3.99M | 129.20K | -7.44M | -8.62M | -11.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Sonnet Biotherapeutics Holdings Inc 주식(SONN)의 최신 뉴스
Chanticleer Holdings Little Big Burger Partner and Brand Ambassador Denny Hamlin Wins the Daytona 500 - marketscreener.com
Sonnet Releases Virtual Investor "What This Means" Segment | SONN Stock News - GuruFocus
Sonnet BioTherapeutics Discusses Positive Safety Data for SON-1010 in Virtual Investor Segment - Nasdaq
Sonnet Releases Virtual Investor "What This Means" Segment - GlobeNewswire
Biotech Leader Dr. Pankaj Mohan Honored on NASDAQ After Tragic Crash - newsindiatimes.com
Sonnet BioTherapeutics (NASDAQ:SONN) Receives Buy Rating from Chardan Capital - Defense World
SONN stock touches 52-week low at $1.18 amid market challenges - Investing.com India
Sonnet BioTherapeutics reports positive results from ovarian cancer therapy trial - Yahoo Finance
Sonnet BioTherapeutics advances in cancer trial - Investing.com Australia
Sonnet BioTherapeutics Says Ovarian Cancer Drug Showed 'Positive' Safety Data in Phase 1b/2a Trial; Shares Up - MarketScreener
Sonnet BioTherapeutics advances in cancer trial By Investing.com - Investing.com South Africa
Sonnet says SON-1010 demonstrates ‘strong safety profile’ in atezolizumab combo - TipRanks
Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose - The Manila Times
Sonnet'S Son-1010 Demonstrates A Strong Safety Profile In Combination With Atezolizumab For Treatment Of Platinum-Resistant Ovarian Cancer - MarketScreener
Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in - GlobeNewswire
Sonnet BioTherapeutics appoints interim CEO and new president By Investing.com - Investing.com Canada
Sonnet Announces Release of Corporate Update Video - GlobeNewswire
Sonnet BioTherapeutics appoints interim CEO and new president - Investing.com
Sonnet BioTherapeutics Announces New Interim CEO Appointment - TipRanks
Pilot Killed In Franklin Twp Plane Crash Was CEO Of Cancer-Focused Biotech Company - NewsBreak: Local News & Alerts
Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D. - citybiz
Sonnet BioTherapeutics appoints interim CEO after founder’s death - Investing.com
Sonnet Announces The Passing Of Founder And CEO Pankaj Mohan - marketscreener.com
Chardan Capital Reaffirms Buy Rating for Sonnet BioTherapeutics (NASDAQ:SONN) - Defense World
Sonnet BioTherapeutics’ (SONN) Buy Rating Reaffirmed at Chardan Capital - The AM Reporter
SONN stock touches 52-week low at $1.28 amid market challenges - Investing.com Australia
Sonnet BioTherapeutics Successfully Completes First Safety - GlobeNewswire
Sonnet BioTherapeutics Successfully Completes First Safety Review Of SON-1010 In Combination With Trabectedin In Certain Sarcomas - MarketScreener
Clinical Trial Success: New Cancer Drug Combo Shows 83% Disease Control in Sarcoma Patients - Stock Titan
Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas - The Manila Times
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Short Interest Up 16.4% in February - Defense World
Sonnet BioTherapeutics secures new IL-18 patent - Investing.com
Sonnet BioTherapeutics secures new IL-18 patent By Investing.com - Investing.com South Africa
Sonnet BioTherapeutics Secures Second Patent for IL-18 Variant - TipRanks
Sonnet BioTherapeutics Receives Notice of Allowance for - GlobeNewswire
Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein - Yahoo
Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire
Sonnet BioTherapeutics Holdings, Inc. Announces Availability of On-Demand Video Webcast Following Virtual Investor "Top 5 for ‘25" Conference - Nasdaq
Sonnet Bio CEO Unveils 5 Game-Changing Developments Coming in 2025 - StockTitan
XRP Plunges as Recession Panic and Crypto Summit Fallout Slam Investors - The Globe and Mail
Sonnet BioTherapeutics Stock Price, Quotes and Forecasts - Benzinga
SONN stock touches 52-week low at $1.33 amid market challenges - Investing.com UK
Sonnet Biotherapeutics Holdings Inc (SONN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
36.06%
자본화:
|
볼륨(24시간):